MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.
Sources
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Inovație în medicina de laborator: MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Latest News
12:42
Yemeni government forces withdraw from the Bab el-Mandeb area to defend the city of Aden
12:30
Romania's radical supporters displayed an antisemitic message at the match against Poland, addressed to MP Silviu Vexler
12:13
SpaceX caught the Starship spacecraft in midair after its return from space / The propulsion rocket exploded during descent
11:46
Bloomberg: The Pentagon is reviewing the plan to withdraw troops from Europe, from 25,000 to approximately 5,000 soldiers
11:21
Bulgaria withdraws its military support for Ukraine and makes any financial aid conditional on the funds being used for civilian purposes
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
